Registry of Hospitalized Patients Treated With Fondaparinux
Deep Vein Thrombosis
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Registry of Hospitalized Patients Treated With Fondaparinux|
- Venous Thromboembolism and Bleeding Events [ Time Frame: 90 Days ] [ Designated as safety issue: No ]
- Mortality [ Time Frame: 30 Days ] [ Designated as safety issue: No ]
|Study Start Date:||July 2007|
|Study Completion Date:||June 2009|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
The use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (VTE) and acute coronary syndrome (ACS). Concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. Fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia.
Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00549705
|Principal Investigator:||Samuel Z Goldhaber, MD||Brigham and Women's Hospital|